

The Active Surveillance for Low-Risk Prostate Cancer: Case Series of Single Center

Düşük Riskli Prostat Kanserleri için Aktif İzlem: Tek Merkezin Olgu Serisi

 Şükrü KUMSAR^a

^aDepartment of Urology, Başkent University İstanbul Hospital, İstanbul, Türkiye

Active surveillance (AS) has become the standard of care for most patients diagnosed with low-risk prostate cancer (PCa).¹

I read with great interest the article by Akarken et al. discussing their initial results with AS for low risk PCa patients.²

In their retrospective study, the data of 36 patients who were included in the AS program in a single center, with the median follow-up period of 18.4 months, have been evaluated.

After reading the article, I propose some considerations for which clarification would be helpful. Although the inclusion criteria were stated as low-risk PCa patients, there were no patients in the study with involvement of more than 3 cores. There is only 1 patient with involvement of 3 biopsy cores. Under this circumstances, these results of the study mostly reflect the results of very low risk patient group.

Although patients with low risk PCa were specified as the inclusion criterion in the study, the ab-

sence of patients with more than 3 biopsy core involvements in the study suggests that there may be a bias in inclusion of very low risk patients in the study.

Source of Finance

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest

No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions

This study is entirely author's own work and no other author contribution.

Correspondence: Şükrü KUMSAR

Department of Urology, Başkent University İstanbul Hospital, İstanbul, Türkiye

E-mail: drkumsar@yahoo.com

Peer review under responsibility of Journal of Reconstructive Urology.

Received: 27 Dec 2021

Accepted: 03 Jan 2022

Available online: 07 Jan 2022

2587-0483 / Copyright © 2022 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



REFERENCES

1. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2019;17(5):479-505. [\[PubMed\]](#)
2. Akarken İ, Bal H, Tarhan H, Deliktaş H, Şahin H. The active surveillance for low-risk prostate cancer: case series of single center. *Journal of Reconstructive Urology*. 2021;11(2):73-8. [\[Crossref\]](#)